Cath Lab Digest

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

When replacing the aortic valve, a small aortic root can limit the size of the prosthetic valve that can be implanted. If the new valve is too small in relation to the patient’s body, the heart must continue to work against increased resistance – a so-called patient-prosthesis mismatch, which is associated with poorer clinical outcomes.

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

WASHINGTON — Exercise should be prescribed as a foundational component of cardiovascular disease (CVD) prevention and treatment, according to a new American College of Cardiology Scientific Statement published today in JACC, its flagship journal. The statement emphasizes that the greatest reduction in cardiovascular risk occurs when sedentary individuals become even modestly more active, and the best exercise prescription is one that is safe, individualized, achievable and sustainable over time.

Palo Alto, Calif. – Recor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announces that the Paradise™ Ultrasound Renal Denervation (uRDN) system has been recognized by TIME with a Best Inventions of 2026 award in the Medical and Healthcare category. The Paradise uRDN system is a device-based, minimally invasive procedure for patients with uncontrolled and resistant hypertension whose blood pressure cannot be properly managed with lifestyle changes and medication.

Atlanta, Georgia — No two pairs of hands are the same, yet surgical glove sizing has changed little over time. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, has listened to what clinicians are saying and is now launching an expanded range of surgical glove fit options.

Abbott announced new real-world data from the PRAISE-HM3 study examining antithrombotic management among patients supported by the HeartMate 3 left ventricular assist device (LVAD). The findings were presented at HFSA 2026 and simultaneously published in the Journal of Cardiac Failure. The study evaluated how clinical practice has changed following publication of the ARIES-HM3 trial and the subsequent FDA labeling update for HeartMate 3.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Cath Lab Digest or HMP Global, their employees, and affiliates. Igor Gosev, MD, PhD Chief, Heart Transplant and Mechanical Circulatory Support (MCS), Newark Beth Israel Medical Center, RWJBarnabas Health, Newark, New Jersey This interview is sponsored by Abbott. This content is the reflection of a single center experience.

JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Cath Lab Digest or HMP Global, their employees, and affiliates. Kimberly Perdue, MBA, RT(R) Independent Cardiovascular Quality and Accreditation Professional, Beckley, West Virginia Kimberly Perdue, MBA, RT(R), can be contacted at kim_2005_wehs@yahoo.com. Disclosure: The author reports no relevant financial relationships.